BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 7662701)

  • 1. Cathepsin D-like aspartyl protease activity mediates the degradation of tissue-type plasminogen activator/plasminogen activator inhibitor-1 complexes in human monocytes.
    Simon DI; Xu H; Vaughan DE
    Biochim Biophys Acta; 1995 Aug; 1268(2):143-51. PubMed ID: 7662701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrinolytic activity of human mesothelial cells is counteracted by rapid uptake of tissue-type plasminogen activator.
    Sitter T; Toet K; Quax P; Kooistra T
    Kidney Int; 1999 Jan; 55(1):120-9. PubMed ID: 9893120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential endocytosis of tissue plasminogen activator by serpins PAI-1 and PAI-2 on human peripheral blood monocytes.
    Lee JA; Croucher DR; Ranson M
    Thromb Haemost; 2010 Dec; 104(6):1133-42. PubMed ID: 20838737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
    Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
    Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular degradation of free and inhibitor-bound tissue-type plasminogen activator--requirement for a co-receptor?
    Camani C; Gavin O; Kruithof EK
    Thromb Haemost; 2000 Feb; 83(2):290-6. PubMed ID: 10739388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocytosis and lysosomal delivery of tissue plasminogen activator-inhibitor 1 complexes in Hep G2 cells.
    Underhill DM; Owensby DA; Morton PA; Schwartz AL
    Blood; 1992 Dec; 80(11):2746-54. PubMed ID: 1333299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Modulation by plasminogen activator inhibitor type 1.
    Morton PA; Owensby DA; Sobel BE; Schwartz AL
    J Biol Chem; 1989 May; 264(13):7228-35. PubMed ID: 2540181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor-mediated endocytosis of tissue-type plasminogen activator by low density lipoprotein receptor-related protein on human hepatoma HepG2 cells.
    Bu G; Maksymovitch EA; Schwartz AL
    J Biol Chem; 1993 Jun; 268(17):13002-9. PubMed ID: 8389767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urokinase binding and catabolism by Hep G2 cells is plasminogen activator inhibitor-1 dependent, analogous to interactions of tissue-type plasminogen activator with these cells.
    Grimsley PG; Normyle JF; Brandt RA; Joulianos G; Chesterman CN; Hogg PJ; Owensby DA
    Thromb Res; 1995 Aug; 79(4):353-61. PubMed ID: 7482438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cathepsin D stimulates the activities of secreted plasminogen activators in the breast cancer acidic environment.
    Maynadier M; Farnoud R; Lamy PJ; Laurent-Matha V; Garcia M; Rochefort H
    Int J Oncol; 2013 Nov; 43(5):1683-90. PubMed ID: 24026424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low density lipoprotein receptor-related protein is necessary for the internalization of both tissue-type plasminogen activator-inhibitor complexes and free tissue-type plasminogen activator.
    Orth K; Willnow T; Herz J; Gething MJ; Sambrook J
    J Biol Chem; 1994 Aug; 269(33):21117-22. PubMed ID: 8063731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the binding of pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library.
    Horn IR; Moestrup SK; van den Berg BM; Pannekoek H; Nielsen MS; van Zonneveld AJ
    J Biol Chem; 1995 May; 270(20):11770-5. PubMed ID: 7538122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells.
    Morton PA; Owensby DA; Wun TC; Billadello JJ; Schwartz AL
    J Biol Chem; 1990 Aug; 265(24):14093-9. PubMed ID: 2167306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the interaction of a complex of tissue-type plasminogen activator and plasminogen activator inhibitor type 1 with rat liver cells.
    Kuiper J; Otter M; Voorschuur AH; van Zonneveld AJ; Rijken DC; van Berkel TJ
    Thromb Haemost; 1995 Nov; 74(5):1298-304. PubMed ID: 8607113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of plasminogen activator inhibitor type 1 in the clearance of tissue-type plasminogen activator by rat hepatoma cells.
    Camani C; Bachmann F; Kruithof EK
    J Biol Chem; 1994 Feb; 269(8):5770-5. PubMed ID: 8119917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular analysis of ligand binding to the second cluster of complement-type repeats of the low density lipoprotein receptor-related protein. Evidence for an allosteric component in receptor-associated protein-mediated inhibition of ligand binding.
    Horn IR; van den Berg BM; van der Meijden PZ; Pannekoek H; van Zonneveld AJ
    J Biol Chem; 1997 May; 272(21):13608-13. PubMed ID: 9153209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium dodecyl sulfate-induced dissociation of complexes between human tissue plasminogen activator and its specific inhibitor.
    Gaussem P; Grailhe P; Anglés-Cano E
    J Biol Chem; 1993 Jun; 268(16):12150-5. PubMed ID: 8505335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.
    Schacke W; Beck KF; Pfeilschifter J; Koch F; Hattenbach LO
    Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2799-805. PubMed ID: 12147618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The interaction of recombinant tissue type plasminogen activator and recombinant plasminogen activator (r-PA/BM 06.022) with human endothelial cells.
    Mulder M; Kohnert U; Fischer S; van Hinsbergh VW; Verheijen JH
    Blood Coagul Fibrinolysis; 1997 Mar; 8(2):124-33. PubMed ID: 9518044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The composition of complexes between plasminogen activator inhibitor 1, vitronectin and either thrombin or tissue-type plasminogen activator.
    van Meijer M; Stoop A; Smilde A; Preissner KT; van Zonneveld AJ; Pannekoek H
    Thromb Haemost; 1997 Mar; 77(3):516-21. PubMed ID: 9066004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.